Tag - Matt Phipps

Markets

WB starts NewAmsterdam Pharma at OP; fair value estimate $19.18

William Blair initiated coverage of NewAmsterdam Pharma (NASDAQ:NAMS) with an “outperform” rating and fair value estimate of $19.18. The stock closed at $12 on Dec. 16. Analyst Matt Phipps, Ph.D., based his rating on...

December 19, 2022

Markets

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

November 14, 2022

Tag - Matt Phipps

WB starts NewAmsterdam Pharma at OP; fair value estimate $19.18

WB starts Janux Therapeutics at OP

General

More